0000899243-18-017491.txt : 20180620 0000899243-18-017491.hdr.sgml : 20180620 20180620202919 ACCESSION NUMBER: 0000899243-18-017491 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180620 FILED AS OF DATE: 20180620 DATE AS OF CHANGE: 20180620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 18910700 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 512-498-2670 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-06-20 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 See Remarks Stock Option (Right to Buy) 1.55 2027-02-04 Common Stock 33686 D Stock Option (Right to Buy) 1.55 2027-06-12 Common Stock 5280 D Stock Option (Right to Buy) 5.93 2028-01-31 Common Stock 17176 D Stock Option (Right to Buy) 5.93 2028-01-31 Common Stock 22457 D Series C Preferred Stock Common Stock 2245 D 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Each share of preferred stock is convertible on a 1.78112-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date. Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs Exhibit 24 - Power of Attorney /s/ Barry Deutsch, as Attorney-in-Fact 2018-06-20 EX-24 2 attachment1.htm EX-24 DOCUMENT


                                 Power of Attorney

       Know all by these presents that the undersigned hereby constitutes and
appoints each of Paul Edick, Barry Deutsch, Beth Hecht and Joseph Theis, and
with full power of substitution, as the undersigned's true and lawful
attorney-in-fact to:

          (1) execute for and on behalf of the undersigned, in the undersigned's
          capacity as a director of Xeris Pharmaceuticals, Inc., a Delaware
          corporation (the "Company"), Forms 3, 4, and 5 in accordance with
          Section 16(a) of the Securities Exchange Act of 1934, as amended, and
          the rules thereunder;
          (2) do and perform any and all acts for and on behalf of the
          undersigned which may be necessary or desirable to complete and
          execute any such Form 3, 4, or 5, complete and execute any amendment
          or amendments thereto, and timely file such form with the SEC and any
          stock exchange or similar authority; and
          (3) take any other action of any type whatsoever in connection with
          the foregoing which, in the opinion of such attorney-in-fact, may be
          of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by such
          attorney-in-fact on behalf of the undersigned pursuant to this Power
          of  Attorney shall be in such form and shall contain such terms and
          conditions as such attorney-in-fact may approve in such
          attorney-infact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. Theundersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 20th day of June, 2018.

/s/ Ken Johnson
------------------------
Name: Ken Johnson